Results 231 to 240 of about 2,210,626 (329)
Software Process Improvement: Continuous Integration and Testing for Web Application Development
Matias Muhonen
openalex +1 more source
ABSTRACT Objective Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker‐defined synucleinopathy.
Daniel Weintraub +24 more
wiley +1 more source
EEG for bedside monitoring: the intensivist's point of view. [PDF]
Taccone FS +3 more
europepmc +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
SurgiGuide: enhancing perioperative patient education with a rule-based digital agent in elective colorectal surgery. [PDF]
Bellini V +4 more
europepmc +1 more source
ABSTRACT Objective We aim to comprehensively analyze how regional tumor and edema characteristics are associated with clinical presentations and survival outcomes in a large cohort of glioblastoma patients. Methods Patients with IDH‐wildtype glioblastoma who received brain MRI from 2010 to 2023 were included.
Daniel J. Zhou +15 more
wiley +1 more source
Implementation of Machine Learning in Heart Failure Trials. [PDF]
Romano LR, Odorico MS, Curcio A.
europepmc +1 more source
MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children
ABSTRACT Objectives The study aimed to characterize the clinical features, etiologies, and outcomes of isolated, first‐time pediatric ON in the post‐MOG‐IgG era. Methods This was a single‐center retrospective cohort study at Texas Children's Hospital of patients diagnosed with first‐time ON between 2018–2024, with follow‐up data collected through 2025.
Chaitanya Aduru +13 more
wiley +1 more source
Autonomous microfluidic labs: progress and prospects.
Damir S +3 more
europepmc +1 more source

